Results 221 to 230 of about 3,585,369 (296)

High <i>p62</i> and <i>ALDH1A3</i> Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer. [PDF]

Cancer Diagn Progn
Maemura Y, Ozaki A, Chiwaki R, Enomoto M, Tada Y, Nagashima Y, Ishii H, Nohata K, Kasai T, Okiyama R, Harada Y, Tamori S, Ohno S, Sasaki K, Akimoto K.   +14 more
europepmc   +1 more source

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

Molecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser, Jan Niklas Schäfer, Shraga Nahum Goldberg, Philipp Maximilian Kazmierczak, Moritz Nikolaus Gröper, Philipp Franz Linden, Elif Öcal, Tanja Burkard, Stefanie Corradini, Najib Ben Khaled, Moritz Wildgruber, Max Seidensticker, Jens Ricke, Matthias Stechele, Marianna Alunni‐Fabbroni   +14 more
wiley   +1 more source

Comorbidity prevalence and incidence in cancer survivors: a longitudinal All of Us study. [PDF]

JNCI Cancer Spectr
Lee JA, Pakpahan R, Amante DJ, Gerber BS, Yang L.   +4 more
europepmc   +1 more source

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

Impact of Population Cancer Risk on the Cost-effectiveness of Multicancer Early Detection Testing in the United States. [PDF]

Cancer Epidemiol Biomarkers Prev
Raoof S, Kansal AR, Tafazzoli A, Ye W, Morris W, Zou D, Fendrick AM.   +6 more
europepmc   +1 more source

Sistemas de saúde, políticas e ações de controle do câncer do colo do útero: Brasil e Chile em perspectiva comparada

, 2020
Itamar Bento Claro
openalex   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Association Between Body Roundness Index and Cancer Risk, With Further Stratification by Cardiometabolic Disease Status: Findings From Three National Longitudinal Cohorts. [PDF]

Cancer Med
Luo P, Lian Y.
europepmc   +1 more source

A synthetic benzoxazine dimer derivative targets c‐Myc to inhibit colorectal cancer progression

Molecular Oncology, EarlyView.
Benzoxazine dimer derivatives bind to the bHLH‐LZ region of c‐Myc, disrupting c‐Myc/MAX complexes, which are evaluated from SAR analysis. This increases ubiquitination and reduces cellular c‐Myc. Impairing DNA repair mechanisms is shown through proteomic analysis.
Nicharat Sriratanasak, Bodee Nutho, Worawat Wattanathana, Narumon Phaonakrop, Bunnatut Panasawatwong, Katharina Erlenbach‐Wuensch, Sittiruk Roytrakul, Regine Schneider‐Stock, Pithi Chanvorachote   +8 more
wiley   +1 more source

Correction: Impact of lymph node dissection on survival after neoadjuvant immunochemotherapy for esophageal squamous cell cancer: a double-center real-world retrospective study. [PDF]

Cancer Immunol Immunother
Huang Y, Lin X, Fang C, Li Z, Chen J, Xie X, Wu H, Yang H, Luo K, Fu J.   +9 more
europepmc   +1 more source